Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. New treatment approved for certain high-risk AML

    ... leaks into the skin and subcutaneous tissue from the intravenous infusion (extravasation). Women who are pregnant or breastfeeding should ...

    Article last updated 08/30/2017 - 7:18am.

  2. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... receive rigosertib 1800 mg per 24 h via 72-h continuous intravenous infusion administered every other week or best supportive care with or ...

    Research Article last updated 06/07/2016 - 11:10am.

  3. SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

    ... with SL-401, which will be administered as a brief intravenous infusion for 3 consecutive days initially every 21 days for 4 cycles; every ...

    Clinical Trial last updated 06/06/2016 - 2:11pm.

  4. Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients

    ... chemotherapy and/or radiation therapy, followed by an infusion of their donor's bone marrow or blood stem cells . The ... Drug: Cytarabine Given by either intrathecal (IT) or intravenous (IV) route. Other Names: Cytosine arabinoside Ara-C ...

    Clinical Trial last updated 05/09/2016 - 3:01pm.

  5. Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

    ... the safety and feasibility of administering a single intravenous dose of CM-CS1 CAR T-cells to patients with AML, MDS-RAEB and ... Biological: CM-CS1 T-cell infusion Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion. ...

    Clinical Trial last updated 05/03/2016 - 9:53am.

  6. Total Marrow Irradiation for Refractory Acute Leukemia

    ... Drug: cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg Other Name: ... Drug: Fludarabine 25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2 Other ...

    Clinical Trial last updated 05/02/2016 - 9:22am.

  7. Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

    ... filgrastim All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count ...

    Clinical Trial last updated 04/29/2016 - 9:56am.

  8. Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation

    ... least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10). Study Arm (s) Experimental: Cohort 1 ... on day -3 at a dose of 3 gram/day divided in 2 or 3 doses. Intravenous (IV) route between days -3 and +5, then may change to PO between ...

    Clinical Trial last updated 04/29/2016 - 1:48pm.

  9. An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

    ... Drug: Azacitidine Azacitidine intravenous or subcutaneous formulation. Drug: Pevonedistat Pevonedistat intravenous infusion. ...

    Clinical Trial last updated 04/28/2016 - 1:58pm.

  10. Busulfan and Cyclophosphamide Followed By ALLO BMT

    ... through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and ... Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional ...

    Clinical Trial last updated 04/29/2016 - 1:23pm.